Table 1 Baseline characteristics and treatment outcomes

Treatment courses (n)

142

104

--

Baseline Characteristics

 Age (years (SD))

64.1 (12.5)

66.7 (12.0)

0.094

 Sex (n, % female)

110 (77%)

79 (73%)

0.418

 Baseline FEV1 (% predicted mean (SD))

80.5 (23.0)

76.4 (23.5)

0.22

 Caucasian (n, %)

88 (62%)

61 (59%)

0.694

 Asian (n, %)

36 (25%)

28 (27%)

0.896

 Other ethnicity (non-Caucasian, non-Asian, n, %)

18 (13%)

15 (14%)

0.835

 Body Mass Index (mean (SD))

21.5 (4.0)

22.3 (5.4)

0.121

 Fibrocavitary Disease (n, %)

34 (24%)

20 (19%)

0.28

 Smear positive (n, %)

28 (20%)

37 (34%)

0.009

 Charlson Comorbidity Index (mean (SD))

4.8 (3.2)

6.1 (4.6)

0.007

 Organ Transplant (n, %)

2 (1.4%)

7 (6.5%)

0.064

 Liver Disease (n, %)

2 (1.4%)

8 (7%)

0.032

 Chronic Kidney Disease Stage 3 or greater (n, %)

6 (4%)

6 (5.5%)

0.798

 Immune Compromise, not HIV (n, %)

24 (17%)

21 (19%)

0.622

 Diabetes (n, %)

7 (5%)

8 (8%)

0.532

 Heart Failure (n, %)

10 (7%)

12 (11%)

0.320

 Ocular Disease (n, %)

27 (19%)

22 (21%)

0.800

 Connective Tissue Disease (n, %)

12 (9%)

15 (14%)

0.203

 GERD (n, %)

36 (25%)

25 (24%)

0.931

Disease Characteristics

 Macrolide sensitive (n, %)

125 (88%)

102 (94%)

0.8721

 Daily therapy (n, %)

109 (77%)

85 (79%)

0.816

 Inhaled amikacin (n, %)

9 (6%)

8 (7%)

0.873

 Amikacin liposomal inhalation suspension (n, %)

7 (5%)

15 (14%)

0.033

 Parenteral amikacin on initiation (n, %)

8 (6%)

8 (7%)

0.932

Outcomes

 Mean treatment duration (months, range)

21 (9–54)

19 (0.5–55)

0.572

 Culture positive at 6 months (n, %)

37 (25%)

45 (43%)

< 0.001

 Recurrence within 12 months (n, %)

28 (20%)

17 (24%)

0.524

 Death from any cause (n, %)

13 (9%)

13 (12%)

0.527